RESTORE: REducing Future fractureS and Improving ouTcOmes of fRagility fracturE

Inclusion Criteria: * Age 50 years and older (no upper age limit) * Sustained a primary fragility fracture (hip/femur, pelvis, clinical spine, humerus, wrist) in the last 12 months * Participant must self-identify a regular primary care provider (PCP) * Participant must provide a mailing address * Participant must plan to remain geographically proximate (able to travel if necessary) to the site from which they are recruited over the next several months Exclusion Criteria: * Exposure to the following medications in the prior 12 months; * Actonel or Atelvia (risedronate) * Fosamax or Binosto (alendronate) * Reclast, Zometa, or Aclasta (zoledronic acid, zoledronate) * Boniva or Bondronat (ibandronate) * Aredia (pamidronate) * Prolia (denosumab) * Evenity (romozosumab) * Tymlos (abaloparatide) * Forteo (teriparatide) * Natpara (parathyroid hormone) * Evista (raloxifene) * Duavee (bazedoxifene-conjugated estrogen) * Miacalcin (calcitonin) * Diagnosis of the following medical conditions; * CKD stage 4 or 5 or on dialysis * Multiple myeloma * Addison's disease * Adrenal insufficiency * Enrolled hospice care * Solid organ transplant, or expecting a solid organ transplant * Bone marrow transplant * History of metabolic bone disease (except osteoporosis) such as Paget's disease, osteomalacia, osteogenesis imperfecta, or Cushing's disease * Fractures resulting from severe trauma (e.g. motor vehicle accidents, a fall from 2 feet or higher elevation) * Pathologic fractures secondary to malignancy or infection * Scheduled appointment with a bone health specialist * Participant unable to consent on their own (cognitive impairment, dementia, etc.) * Currently enrolled in another research study that requires taking medication